As we head into 2026, the Cell & Gene Therapy (CGT) sector is shifting its focus from clinical milestones to commercial viability and pragmatic execution. 

We are proud to share that Autolomous leadership contributed to the Cell & Gene Therapy Review’s ‘2026 predictions,’ with CEO, Alexander Seyf, and VP of Product Commercialization, Alexa Crăciunescu, highlighting the transition toward mandatory, scalable industrialization. Alexander notes that the “automation imperative” is the only way to combat high costs and ensure the data integrity required by modern regulators, while Alexa emphasizes that success now hinges on verifiable ROI and unified digital ecosystems that eliminate batch failures.

As the industry moves from proof-of-concept to proof-of-practicality, Autolomous remains committed to providing the digital infrastructure that transforms these complex therapies into accessible, commercial realities.

To read the full article, click here.